Overview
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.
Faculty discussion will focus on:
• Recognizing and diagnosing EoE
• Treating EoE as a chronic disease
• Novel developments in treatment
This activity is designed for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.
EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.
Upon completion of this activity, participants will be able to:
• Identify patients with EoE using the latest diagnostic recommendations and criteria
• Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
• Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
• Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
• Indicate the potential roles of investigational treatments in EoE management plans
• Identify patients with EoE using the latest diagnostic recommendations and criteria
• Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
• Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
• Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
• Indicate the potential roles of investigational treatments in EoE management plans
Video Modules
Introduction to EoE and Its Diagnosis
EoE: A Chronic Disease With Unmet Treatment Needs
It Takes a Village: Interdisciplinary Care for EoE
Introduction to EoE and Its Diagnosis
EoE: A Chronic Disease With Unmet Treatment Needs
It Takes a Village: Interdisciplinary Care for EoE
Digital Infographic
Practical Points for the Diagnosis and Chronic Treatment of EoE
Sponsored by the Academy for Continued Healthcare Learning.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC
Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC
Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO
Robbie Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda
Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose
Gary Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda
Calies Menard Katcher, MD, MSCS
Nothing to disclose
Robert Pesek, MD
Nothing to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
